Hopital Europeen Georges-Pompidou — Paris

Public research footprint of Hopital Europeen Georges-Pompidou, compiled from the ClinicalTrials.gov public registry.

196

Registered studies

Active

Recruiting now

120

Completed

Stopped or withdrawn

Most-studied conditions

Urinary Bladder Neoplasms · HER2-(Ultra)Low Expressing Breast Cancer · Urinary Bladder Cancer, Muscle-invasive · Gastroesophageal Junction Adenocarcinoma

Recently updated registry entries

NCT05663866 — Premedication to Reduce Amivantamab Associated Infusion Related Reactions (Active Not Recruiting)
NCT04640623 — A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in… (Active Not Recruiting)
NCT05901649 — A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)… (Completed)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hopital Europeen Georges-Pompidou?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.